Abstract: The present invention relates to a novel compound which can function as a molecular glue, or an enantiomeric compound thereof, and a method for preparing these compounds and uses thereof.

Abstract: The present invention relates to use of a novel compound for prevention or treatment of brain cancer, where the novel compound may function as a molecular gluc.

Abstract: The present disclosure relates to medical use of a compound of chemical formula 1 for treatment or prevention of pulmonary fibrosis. The present disclosure also relates to combination therapy with the compound of chemical formula 1 and nintedanib.

Abstract: The present invention provides: novel compounds capable of producing monomethyl fumarate after the compounds are administered; pharmaceutical compositions comprising same as active ingredients; and pharmaceutical uses thereof for treating or alleviating various diseases including immune system abnormalities, neurodegeneration, and/or inflammatory diseases.

Abstract: The present invention relates to a medical use of a compound, of Chemical Formula 1, for treating, alleviating or preventing non-alcoholic steatohepatitis (NASH) and/or hepatic fibrosis.

Abstract: A liquid preparation and a method for preparing the liquid preparation are disclosed. The liquid preparation contains a high-concentration L-serine or a pharmaceutically acceptable salt thereof, and shows an excellent stability and safety. The liquid preparation exhibits excellent pharmacological effects and is suitable for preventing or treating a central nervous system disease.

Abstract: The present disclosure provides a compound of a specific chemical structure or a pharmaceutically acceptable salt thereof, which has the activity of inhibiting and/or degrading mutant EGFR protein. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of cancer with EGFR mutation, especially lung cancer. The present disclosure also provides a method for treatment or prevention of EGFR mutation cancer, especially lung cancer, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing same to a subject in need of treatment.

Abstract: The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duchenne muscular atrophy, and a medicinal use of the novel compound.

Abstract: The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.

Abstract: The present invention provides novel pyrimidine derivative compounds inhibiting growth of cancer cells and pharmaceutically acceptable salts thereof. The present invention provides a pharmaceutical composition comprising these compounds or pharmaceutically acceptable salts. The present invention also provides a medical use for treatment of lung cancer, characterized by using these pyrimidine derivative compounds and pharmaceutically acceptable salts thereof as an active ingredient. The present invention also provides a method for treatment of lung cancer comprising administering an effective dose of compounds according to the present invention, salts thereof or a composition comprising them.

Abstract: The present invention relates to a novel compound and a medicinal use of the novel compound. In particular, the present invention relates to a novel compound useful for the treatment and/or prevention of muscular dystrophy, including Duchenne muscular atrophy, and a medicinal use of the novel compound.

Abstract: The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.

Abstract: The present invention provides: novel compounds capable of producing monomethyl fumarate after the compounds are administered; pharmaceutical compositions comprising same as active ingredients; and pharmaceutical uses thereof for treating or alleviating various diseases including immune system abnormalities, neurodegeneration, and/or inflammatory diseases.

Abstract: The present invention relates to a medical use of a compound, of Chemical Formula 1, for treating, alleviating or preventing non-alcoholic steatohepatitis (NASH) and/or hepatic fibrosis.

Abstract: A novel pyrimidine derivative compound and a salt thereof are disclosed. The pyrimidine derivative compound effectively inhibits the growth of C797S mutant EGFR-expressed and MET-amplified cancer cells, which are the main resistance mechanisms of third generation EGFR anticancer agents, and thus may be effectively used in the treatment of lung cancer.

Abstract: The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.

Abstract: The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A pharmaceutical composition comprising i) at least one composition that has affinity to the ?-opioid receptor, and at least one compound that has affinity to the VR1 receptor, or ii) at least one compound, in particular at least one compound corresponding to formula (I), (II), (III), (IV) or (V), that has affinity to the ?-opioid receptor and to the VR1 receptor, and also to the use of the pharmaceutical compositions i) and ii) for the production of a drug for the treatment of pain.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.